

How health research supported by NHS Wales benefits the economy

An independent report, commissioned by Health and Care Research Wales¹ and produced by KPMG's Economics team, provides an assessment of the economic impact and value generated through health research activity undertaken in NHS Wales over the financial year 2018/19.

The report includes an assessment of the contribution made to the economy through health research studies supported by NHS Wales; an analysis to quantify the monetary value of health research to NHS Wales (specifically the value to the NHS of pharmaceuticals provided and the payments made to NHS organisations for the delivery of commercial studies); and an analysis of the wider impacts generated by Health and Care Research Wales' Support & Delivery Service. The key findings are below.

NHS Wales supported health research activity which generated:





In 2018/19, the NHS in Wales:









Total estimated cost saving to NHS Wales of pharmaceutical products provided free of charge in 2018/19 studies:



Between 2015/16 to 2018/19, the number of:

Studies on our portfolio³ increased by

The Support & Delivery Service's One Wales approach is highly attractive for conducting health research as it speeds up the contracting processes (through the standardised approach for reviewing and agreeing contracts and costings) and is more efficient. Based on industry feedback.

Please see the for details of the analysis.

For more information, contact:

economic value of the activity.

The portfolio is a subset of the Health and Care Research Wales directory, consisting of commercial and non-commercial research. Only 'high-quality' research is included on the portfolio.

¹Funded by the Welsh Government's Research & Development Division.
² Gross value added measures the contribution to the economy of an individual producer, industry or sector, net of intermediate consumption (for example goods and services that are used in the production process). It is a measure of the